Compare Docusign Inc (DOCU) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Moderna, Inc. — how do they compare? Docusign Inc trades at $70.37 (market cap $13.35B), while Moderna, Inc. trades at $220.17 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 5.9× Docusign Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Moderna, Inc. for 59 Days on average.
| DOCU | MRNA | |
|---|---|---|
Market Cap | $13.35B | $78.65B |
Volume | 3,158,858 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $73.14 | $203.46 |
52-Week Low | $41.75 | $22.36 |
Typical Hold Time | 71 Days | 59 Days |
Enterprise Value | $12.76B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $70.08, up 1.71% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.98 billion in 2025, with net income surging to $1.07 billion, though cash flow turned negative. Recent news highlights AI integration in contract processing and leadership in workflow software.
Outlook remains positive with continued earnings momentum and AI-driven growth, but risks include insider selling and competitive pressures. The stock offers growth potential but requires monitoring of cash flow trends and market saturation in e-signature adoption.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
